Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK Long-term Debt

Borrowings due after more than one year.

Outlook Therapeutics, Inc.NASDAQ: OTLK

Long-term Debt · Q2 FY2026 · quarter ended Mar 2026

Long-term debt falls 47.1% from a year ago

Long-term debt stood at $11.12M at the end of Q2 FY2026, down 47.1% from a year earlier.

Context

  • Long-term debt amounted to 50.8% of total assets at the end of Q2 FY2026, down 59.5 pp from a year earlier.
  • Long-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -47.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.12M— QoQ
Last fiscal yearSep 2025
$0— YoY
Year agoMar 2025
$21.05M-47.1% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.1%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Long-term Debt vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's Mar 2026 long-term debt of $11.12M is the 2nd highest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of -47.1% is the highest of 3, against a peer median of -100.0%.
  • Long-term debt amounts to 50.8% of total assets for OTLK, versus a peer median of 0.0%.
OTLK Competitors Peer median
Long-term Debt for OTLK and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IPSCCentury Therapeutics, Inc.Mar 2026$43.94M ——13.5%
OTLKOutlook Therapeutics, Inc.Mar 2026$11.12M -47.1%—50.8%
SPRBSpruce Biosciences, Inc.Mar 2026$5.46M —-49.7%9.7%
EQEquillium, Inc.Mar 2026$251K —-52.1%0.4%
CUECue Biopharma, Inc.Mar 2026$0 ——0.0%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
HOWLWerewolf Therapeutics, Inc.Jun 2026$0 -100.0%—0.0%
COEPCoeptis Therapeutics, Inc.Mar 2026$0 -100.0%+0.0%0.0%
OSTXOS Therapies IncorporatedMar 2026$0 ——0.0%
Peer median (excluding OTLK) $0-100.0%-49.7%0.0%

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Cash & Equivalents14.48M17.4M23.39M14.93M8.08M
Short-term Investments00000
Net Receivables00001.49M
Inventory00003.34M
Other Current Assets32407.59M12.49M4.48M
Total Current Assets21.51M27.52M30.98M27.42M17.39M
Property, Plant & Equipment (Net)275.05K70.36K26.17K274.65K225.51K
Goodwill00000
Intangible Assets00000
Long-term Investments853.66K804.93K793.93K693.19K552.18K
Tax Assets00000
Other Non-current Assets174.59K132.02K501.3K439.28K417.52K
Total Non-current Assets1.3M1.01M1.32M1.41M1.2M
Total Assets22.81M28.53M32.3M28.82M18.58M
Account Payables2.2M3.49M6.57M7.97M10.19M
Short-term Debt904.2K10.92M35.55M29.44M29.95M
Tax Payables1.86M1.86M1.86M1.86M302B
Deferred Revenue00000
Other Current Liabilities(217)1.45M1.83M1.01M3.03M
Total Current Liabilities6.75M19.73M46.73M42.55M45.81M
Long-term Debt10.89M0000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities522.92K57.14K6.22K59.1M4.77M
Total Non-current Liabilities11.45M61.41K6.22K59.35M4.96M
Total Liabilities18.2M19.79M46.74M101.9M50.77M
Common Stock1.76M2.27M2.6M239.06K538.87K
Retained Earnings(342.88M)(408.94M)(467.92M)(543.28M)(605.71M)
Accumulated OCI(22.81T)417.67M(32.3T)00
Other Stockholders Equity(167)(28.53T)000
Minority Interest00000
Total Equity4.61M8.74M(14.44M)(73.08M)(32.19M)
Total Debt11.9M10.96M35.56M29.74M30.19M
Net Debt(2.57M)(6.44M)12.16M14.81M22.11M

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.